Agilent Technologies Inc (NYSE:A) Director Heidi Fields Sells 4,000 Shares of Stock

Agilent Technologies Inc (NYSE:A) Director Heidi Fields sold 4,000 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $70.96, for a total transaction of $283,840.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Agilent Technologies stock traded up $0.70 during midday trading on Friday, hitting $74.22. The stock had a trading volume of 189,547 shares, compared to its average volume of 2,344,661. The firm’s fifty day moving average is $69.62 and its two-hundred day moving average is $74.07. The company has a market capitalization of $22.75 billion, a PE ratio of 26.62, a P/E/G ratio of 1.96 and a beta of 1.40. Agilent Technologies Inc has a 52-week low of $61.01 and a 52-week high of $82.27. The company has a current ratio of 2.13, a quick ratio of 1.72 and a debt-to-equity ratio of 0.27.

Agilent Technologies (NYSE:A) last released its earnings results on Wednesday, August 14th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.04. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.24 billion. Agilent Technologies had a net margin of 21.06% and a return on equity of 20.00%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. As a group, equities research analysts predict that Agilent Technologies Inc will post 3.08 earnings per share for the current fiscal year.

A has been the subject of several research reports. Needham & Company LLC upped their price target on shares of Agilent Technologies to $92.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Piper Jaffray Companies upped their price target on shares of Agilent Technologies from $83.00 to $86.00 and gave the company an “overweight” rating in a research report on Thursday, August 15th. Wolfe Research initiated coverage on shares of Agilent Technologies in a research report on Thursday, May 30th. They set a “peer perform” rating for the company. Barclays lowered shares of Agilent Technologies from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $86.00 to $78.00 in a research report on Monday, July 15th. Finally, Bank of America lowered shares of Agilent Technologies from a “buy” rating to a “neutral” rating and set a $76.00 price target for the company. in a research report on Tuesday, July 16th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Agilent Technologies currently has a consensus rating of “Buy” and an average target price of $84.77.

Institutional investors have recently added to or reduced their stakes in the stock. Edgestream Partners L.P. purchased a new stake in Agilent Technologies in the 2nd quarter worth approximately $2,616,000. Stratos Wealth Partners LTD. increased its holdings in Agilent Technologies by 2.7% in the 1st quarter. Stratos Wealth Partners LTD. now owns 31,792 shares of the medical research company’s stock worth $2,555,000 after acquiring an additional 850 shares in the last quarter. Prentiss Smith & Co. Inc. increased its holdings in Agilent Technologies by 484.9% in the 2nd quarter. Prentiss Smith & Co. Inc. now owns 58,428 shares of the medical research company’s stock worth $4,363,000 after acquiring an additional 48,438 shares in the last quarter. TimesSquare Capital Management LLC increased its holdings in Agilent Technologies by 0.7% in the 1st quarter. TimesSquare Capital Management LLC now owns 1,007,700 shares of the medical research company’s stock worth $80,999,000 after acquiring an additional 7,200 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in Agilent Technologies by 510.5% in the 1st quarter. Nordea Investment Management AB now owns 112,292 shares of the medical research company’s stock worth $9,028,000 after acquiring an additional 93,898 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Read More: What is the Producer Price Index (PPI)?

Insider Buying and Selling by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.